News stories about Ocular Therapeutix (NASDAQ:OCUL) have been trending positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ocular Therapeutix earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.1863608611533 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Ocular Therapeut Has Returned 35.6% Since SmarTrend Recommendation (OCUL) (mysmartrend.com)
- Only the Technical Indicators on Ocular Therapeutix, Inc. (OCUL) – Wall Street Morning (wallstreetmorning.com)
- Ocular Therapeutix Inc (OCUL) Given Consensus Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Hot Stock That Must Be … – Nasdaq Journal (nasdaqjournal.com)
- Active Stock Evaluation – Ocular Therapeutix, Inc. (NASDAQ: OCUL) – The Investor Guide (wallstreetnews24.com)
Shares of Ocular Therapeutix stock opened at $7.04 on Thursday. The firm has a market capitalization of $255.73, a price-to-earnings ratio of -3.20 and a beta of 1.51. Ocular Therapeutix has a 52-week low of $3.30 and a 52-week high of $11.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.22 and a current ratio of 3.23.
A number of equities analysts have commented on OCUL shares. BTIG Research raised Ocular Therapeutix from a “neutral” rating to a “buy” rating in a research note on Friday, January 19th. ValuEngine downgraded Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research report on Tuesday, March 13th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Ocular Therapeutix in a research report on Friday, March 9th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $22.00 target price on shares of Ocular Therapeutix in a research report on Thursday, March 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $11.70.
TRADEMARK VIOLATION NOTICE: “Favorable News Coverage Somewhat Unlikely to Impact Ocular Therapeutix (OCUL) Stock Price” was first published by BBNS and is owned by of BBNS. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://baseballnewssource.com/2018/03/22/positive-media-coverage-somewhat-unlikely-to-impact-ocular-therapeutix-ocul-share-price/1925231.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.